- Home
- PRLD vs PDSB Comparison
PRLD vs PDSB Comparison
Compare PRLD & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- PDSB
- Stock Information
- Founded
- PRLD 2016
- PDSB 2005
- Country
- PRLD United States
- PDSB United States
- Employees
- PRLD N/A
- PDSB N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- PDSB Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- PDSB Health Care
- Exchange
- PRLD Nasdaq
- PDSB Nasdaq
- Market Cap
- PRLD 73.7M
- PDSB 84.2M
- IPO Year
- PRLD 2020
- PDSB N/A
- Fundamental
- Price
- PRLD $1.05
- PDSB $1.45
- Analyst Decision
- PRLD Strong Buy
- PDSB Strong Buy
- Analyst Count
- PRLD 2
- PDSB 3
- Target Price
- PRLD $4.50
- PDSB $14.00
- AVG Volume (30 Days)
- PRLD 611.2K
- PDSB 296.4K
- Earning Date
- PRLD 02-13-2025
- PDSB 11-14-2024
- Dividend Yield
- PRLD N/A
- PDSB N/A
- EPS Growth
- PRLD N/A
- PDSB N/A
- EPS
- PRLD N/A
- PDSB N/A
- Revenue
- PRLD $3,000,000.00
- PDSB N/A
- Revenue This Year
- PRLD N/A
- PDSB N/A
- Revenue Next Year
- PRLD N/A
- PDSB N/A
- P/E Ratio
- PRLD N/A
- PDSB N/A
- Revenue Growth
- PRLD N/A
- PDSB N/A
- 52 Week Low
- PRLD $0.80
- PDSB $1.30
- 52 Week High
- PRLD $6.80
- PDSB $6.68
- Technical
- Relative Strength Index (RSI)
- PRLD 45.27
- PDSB 34.16
- Support Level
- PRLD $0.98
- PDSB $1.37
- Resistance Level
- PRLD $1.43
- PDSB $1.50
- Average True Range (ATR)
- PRLD 0.12
- PDSB 0.13
- MACD
- PRLD -0.02
- PDSB 0.00
- Stochastic Oscillator
- PRLD 14.14
- PDSB 28.03
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.